SCHEMBL23924376

SCHEMBL23924376

O=C(O)N1C[C@H](NC(=S)Nc2cccc3cnccc23)[C@@H](c2ccccc2)C1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.53
HTT P42858 5/20 0.53
MEN1 O00255 3/20 0.53
BLM P54132 2/20 0.53
MAPK1 P28482 1/20 0.53
MAPT P10636 13/20 0.49
ALDH1A1 P00352 13/20 0.49
KDM4E B2RXH2 11/20 0.49
SMN1; SMN2 Q16637 7/20 0.49
NPC1 O15118 1/20 0.48
GALR3 O60755 1/20 0.48
NR2F2 P24468 1/20 0.48
GALK1 P51570 1/20 0.47
ATM Q13315 1/20 0.47
LMNA P02545 4/20 0.47
NSD2 O96028 1/20 0.47
THRB P10828 1/20 0.45
HPGD P15428 1/20 0.45
CASP3 P42574 1/20 0.45
SENP8 Q96LD8 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23924378 1.00 KMT2A (0.53) KMT2AHTTMEN1BLMMAPK1
SCHEMBL23951374 0.88 KMT2A (0.47) KMT2AHTTMEN1BLMMAPK1
SCHEMBL23924317 0.83 ALDH1A1 (0.53) KMT2AHTTMEN1BLMMAPK1
SCHEMBL23951604 0.83 ALDH1A1 (0.53) KMT2AHTTMEN1BLMMAPK1
SCHEMBL23924172 0.82 TRPV1 (0.47) KMT2AHTTMEN1BLMMAPK1
SCHEMBL23924282 0.82 TRPV1 (0.47) KMT2AHTTMEN1BLMMAPK1
SCHEMBL23924118 0.82 TRPV1 (0.47) KMT2AHTTMEN1BLMMAPK1
SCHEMBL23924170 0.82 TRPV1 (0.47) KMT2AHTTMEN1BLMMAPK1
SCHEMBL23924493 0.82 TRPV1 (0.47) KMT2AHTTMEN1BLMMAPK1
SCHEMBL23924011 0.82 KMT2A (0.48) KMT2AHTTMEN1BLMMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220213061-A9 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 TES PHARMA S.R.L. (IT) 2022-07-07 US disclosed
US-20210323942-A1 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 TES PHARMA S R L (IT) 2021-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220213061-A9 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 NR2E3, NR2F2, NR2C2 KMT2A 1332/4885HTT 1219/4885MEN1 4081/4885
US-20210323942-A1 HETEROCYCLIC COMPOUNDS FOR MODULATING NR2F6 NR2E3, NR2F2, NR2C2 KMT2A 1332/4885HTT 1219/4885MEN1 4081/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.